Phase 3 Liver Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with a malignant (cancerous) liver tumour and are being considered for a specific major liver surgery that removes a large portion of the liver
- People who have given their consent to take part
- People aged 18 or older
- People whose remaining liver (after surgery) is estimated to be 30% or less of the expected healthy liver size
- People whose liver's ability to clear a specific dye (called indocyanine green) at 15 minutes falls below a certain threshold (confirm with trial site)
- People with a platelet count above 100 x 10⁹/L (a blood measurement related to clotting)
- People with mild (Child A stage) liver cirrhosis caused by hepatitis B or C, alcohol, or an autoimmune condition
- People considered low-to-moderate risk for anaesthesia, based on a standard anaesthesia scoring system (score below 3)
- People with a general health and activity level rated at 0, 1, or 2 on a standard cancer performance scale (meaning able to carry out daily activities with little to no limitation)
- People whose liver anatomy includes a single long-segment portal vein, which makes them technically suitable for the keyhole surgical approach used in this trial
Who may not be able to join:
- People who have not given their consent
- People with advanced liver disease showing signs such as fluid build-up in the abdomen, enlarged veins in the digestive tract, or confusion caused by liver failure
- People with a general health and activity level rated 3 or higher on the standard cancer performance scale (meaning significant limitations in daily activity)
- People who have a blood clot in the main portal vein of the liver
- People whose remaining liver (after surgery) is estimated to be more than 30% of the expected healthy liver size
- People whose portal vein anatomy is not suitable for the keyhole surgical approach — for example, a short segment, early branching, or other abnormalities of the portal vein
- People whose tumour is larger than 5 cm in diameter
- People who cannot tolerate the carbon dioxide gas used during keyhole (laparoscopic) surgery
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Albert Chan, The University of Hong Kong
Phone: +85222553025
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Amount of future liver remnant volume increment by percentage after stage I ALPPS
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.